The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Allarity filed a current report on Form 8-K with the SEC on July 22, 2024. The filing reveals that the Company received a “Wells Notice” from the SEC. The Company stated in its filing that, “the Wells Notice relates to the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the ‘FDA’) regarding the Company’s NDA [New Drug Application] for Dovitinib or Dovitinib-DRP,” and that “Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct.” Additionally, “the Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws.”

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724877083/en/